美国应对特应性皮炎的挑战。

IF 1.4 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES American Health and Drug Benefits Pub Date : 2019-04-01
Steven R Feldman, Linda S Cox, Lindsay C Strowd, Robert A Gerber, Steven Faulkner, Debra Sierka, Timothy W Smith, Joseph C Cappelleri, Mark E Levenberg
{"title":"美国应对特应性皮炎的挑战。","authors":"Steven R Feldman,&nbsp;Linda S Cox,&nbsp;Lindsay C Strowd,&nbsp;Robert A Gerber,&nbsp;Steven Faulkner,&nbsp;Debra Sierka,&nbsp;Timothy W Smith,&nbsp;Joseph C Cappelleri,&nbsp;Mark E Levenberg","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis is a chronic inflammatory skin disease that affects up to 13% of children and 10% of adults in the United States. Among patients and their families, atopic dermatitis has a considerable effect on quality of life and represents a substantial economic burden.</p><p><strong>Objective: </strong>To describe the impact and challenges of atopic dermatitis and to provide nondermatologists in the healthcare community an enhanced understanding of atopic dermatitis to facilitate treatment and pharmacy benefit discussions.</p><p><strong>Discussion: </strong>Atopic dermatitis is a heterogeneous disease, and its diagnosis is hampered by a lack of objective diagnostic criteria. The current management guidelines address the distinct clinical phenotypes as a single disease and do not incorporate recent clinical advances, such as the targeting of specific inflammatory processes. The treatment guidelines for atopic dermatitis are complex and challenge healthcare providers, patients, and caregivers. Novel treatments can provide additional therapeutic options for patients with atopic dermatitis.</p><p><strong>Conclusions: </strong>Treatment options for atopic dermatitis are expanding with the development of novel anti-inflammatory therapies. An increased understanding of these advancements is necessary to optimize care for patients with atopic dermatitis.</p>","PeriodicalId":48595,"journal":{"name":"American Health and Drug Benefits","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485648/pdf/ahdb-12-083.pdf","citationCount":"0","resultStr":"{\"title\":\"The Challenge of Managing Atopic Dermatitis in the United States.\",\"authors\":\"Steven R Feldman,&nbsp;Linda S Cox,&nbsp;Lindsay C Strowd,&nbsp;Robert A Gerber,&nbsp;Steven Faulkner,&nbsp;Debra Sierka,&nbsp;Timothy W Smith,&nbsp;Joseph C Cappelleri,&nbsp;Mark E Levenberg\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Atopic dermatitis is a chronic inflammatory skin disease that affects up to 13% of children and 10% of adults in the United States. Among patients and their families, atopic dermatitis has a considerable effect on quality of life and represents a substantial economic burden.</p><p><strong>Objective: </strong>To describe the impact and challenges of atopic dermatitis and to provide nondermatologists in the healthcare community an enhanced understanding of atopic dermatitis to facilitate treatment and pharmacy benefit discussions.</p><p><strong>Discussion: </strong>Atopic dermatitis is a heterogeneous disease, and its diagnosis is hampered by a lack of objective diagnostic criteria. The current management guidelines address the distinct clinical phenotypes as a single disease and do not incorporate recent clinical advances, such as the targeting of specific inflammatory processes. The treatment guidelines for atopic dermatitis are complex and challenge healthcare providers, patients, and caregivers. Novel treatments can provide additional therapeutic options for patients with atopic dermatitis.</p><p><strong>Conclusions: </strong>Treatment options for atopic dermatitis are expanding with the development of novel anti-inflammatory therapies. An increased understanding of these advancements is necessary to optimize care for patients with atopic dermatitis.</p>\",\"PeriodicalId\":48595,\"journal\":{\"name\":\"American Health and Drug Benefits\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2019-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485648/pdf/ahdb-12-083.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Health and Drug Benefits\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Health and Drug Benefits","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:特应性皮炎是一种慢性炎症性皮肤病,在美国影响多达13%的儿童和10%的成年人。在患者及其家属中,特应性皮炎对生活质量有相当大的影响,并代表着巨大的经济负担。目的:描述特应性皮炎的影响和挑战,并为医疗保健界的非变态反应学家提供对特应性皮肤炎的更多了解,以促进治疗和药物效益的讨论。讨论:特应性皮炎是一种异质性疾病,由于缺乏客观的诊断标准,其诊断受到阻碍。目前的管理指南将不同的临床表型作为一种疾病来处理,并且没有纳入最近的临床进展,例如针对特定炎症过程。特应性皮炎的治疗指南很复杂,对医疗保健提供者、患者和护理人员都有挑战。新的治疗方法可以为特应性皮炎患者提供额外的治疗选择。结论:随着新型抗炎疗法的发展,特应性皮炎的治疗选择正在扩大。对这些进展的进一步了解对于优化特应性皮炎患者的护理是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Challenge of Managing Atopic Dermatitis in the United States.

Background: Atopic dermatitis is a chronic inflammatory skin disease that affects up to 13% of children and 10% of adults in the United States. Among patients and their families, atopic dermatitis has a considerable effect on quality of life and represents a substantial economic burden.

Objective: To describe the impact and challenges of atopic dermatitis and to provide nondermatologists in the healthcare community an enhanced understanding of atopic dermatitis to facilitate treatment and pharmacy benefit discussions.

Discussion: Atopic dermatitis is a heterogeneous disease, and its diagnosis is hampered by a lack of objective diagnostic criteria. The current management guidelines address the distinct clinical phenotypes as a single disease and do not incorporate recent clinical advances, such as the targeting of specific inflammatory processes. The treatment guidelines for atopic dermatitis are complex and challenge healthcare providers, patients, and caregivers. Novel treatments can provide additional therapeutic options for patients with atopic dermatitis.

Conclusions: Treatment options for atopic dermatitis are expanding with the development of novel anti-inflammatory therapies. An increased understanding of these advancements is necessary to optimize care for patients with atopic dermatitis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American Health and Drug Benefits
American Health and Drug Benefits Medicine-Health Policy
CiteScore
2.90
自引率
0.00%
发文量
4
期刊介绍: AHDB welcomes articles on clinical-, policy-, and business-related topics relevant to the integration of the forces in healthcare that affect the cost and quality of healthcare delivery, improve healthcare quality, and ultimately result in access to care, focusing on health organization structures and processes, health information, health policies, health and behavioral economics, as well as health technologies, products, and patient behaviors relevant to value-based quality of care.
期刊最新文献
Migration of Hospital Total Hip and Knee Arthroplasty Procedures to an Ambulatory Surgery Center Setting and Postsurgical Opioid Use: A Private Practice Experience. Characterizing Cardiac Catheterization Utilization in a US Population with Commercial or Medicare Advantage Health Plans. Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence. Medication Optimization: Integration of Comprehensive Medication Management into Practice. Thinking About 2030.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1